What is HC Wainwright’s Estimate for CGTX Q1 Earnings?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Analysts at HC Wainwright issued their Q1 2026 earnings estimates for Cognition Therapeutics in a research note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.08) per share for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Cognition Therapeutics’ Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS and Q4 2026 earnings at ($0.07) EPS.

Cognition Therapeutics (NASDAQ:CGTX) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). During the same quarter last year, the company posted ($0.27) EPS.

Several other equities analysts have also recently weighed in on CGTX. Chardan Capital cut their price objective on Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, March 21st. Brookline Capital Management upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. Finally, B. Riley upgraded shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the company from $1.00 to $1.50 in a report on Thursday, December 19th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $7.50.

Cognition Therapeutics Trading Down 6.2 %

NASDAQ:CGTX opened at $0.46 on Tuesday. Cognition Therapeutics has a 1 year low of $0.34 and a 1 year high of $2.95. The stock has a 50-day moving average price of $0.57 and a two-hundred day moving average price of $0.55. The stock has a market cap of $19.08 million, a price-to-earnings ratio of -0.47 and a beta of 1.03.

Institutional Trading of Cognition Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Two Sigma Investments LP increased its stake in Cognition Therapeutics by 372.2% in the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock valued at $38,000 after buying an additional 42,321 shares during the last quarter. Voss Capital LP acquired a new position in shares of Cognition Therapeutics during the 4th quarter worth about $351,000. Geode Capital Management LLC grew its holdings in shares of Cognition Therapeutics by 8.9% in the 4th quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock valued at $247,000 after acquiring an additional 28,705 shares in the last quarter. Virtu Financial LLC increased its position in shares of Cognition Therapeutics by 40.1% in the fourth quarter. Virtu Financial LLC now owns 80,180 shares of the company’s stock valued at $56,000 after acquiring an additional 22,949 shares during the last quarter. Finally, BIOS Capital Management LP bought a new stake in Cognition Therapeutics during the fourth quarter worth about $4,208,000. Institutional investors own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.